 Connection
Samer Al Hadidi to United States
This is a "connection" page, showing publications Samer Al Hadidi has written about United States.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.979 |
|
|
|
-
Altarawneh H, Manasrah M, Al Shanableh Y, Saed Aldien A, Manasrah MA, Khan S, Altarawneh L, Al-Kraimeen LM, Al Kasaji F, Alareeki A, Al Hadidi S. Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis. J Cancer Policy. 2024 Jun; 40:100484.
Score: 0.111
-
Chakraborty R, Al Hadidi S. Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States. J Clin Oncol. 2023 07 10; 41(20):3657-3658.
Score: 0.104
-
Al Hadidi S, Abu Zaid MI, Mustafa Ali M. Institutional disparities in the distribution of the American Society of Clinical Oncology grants. J Cancer Policy. 2023 03; 35:100404.
Score: 0.101
-
Syaj S, Al-Kraimeen L, Akhdar M, Abushukair H, Mohty R, Al Hadidi S. Gender and early-career faculty disparities in hematology and?oncology board review lecture series. Blood Adv. 2022 12 27; 6(24):6213-6218.
Score: 0.101
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
Score: 0.096
-
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16.
Score: 0.094
-
Al Hadidi S, Dongarwar D, Salihu HM, Kamble RT, Lulla P, Hill LC, Carrum G, Ramos CA, Heslop HE, Usmani SZ. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
Score: 0.091
-
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
Score: 0.088
-
Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322.
Score: 0.085
-
Patel T, Chen C, Al Hadidi S, Kadry Y, Sridhara R, Purcell E, Wisch L, Retzlaff J, Foti M, Pazdur R, Kluetz P, Gao J. Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational Fellowship. Clin Cancer Res. 2024 Aug 01; 30(15):3144-3146.
Score: 0.028
-
Persaud S, Al Hadidi S, Anderson TS, Gallagher G, Chimonas S, Korenstein D, Mitchell AP. Industry Payments to Physicians Endorsing Drugs and Devices on a Social Media Platform. JAMA. 2024 06 25; 331(24):2131-2134.
Score: 0.028
-
Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757.
Score: 0.026
-
Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022 08; 8:e2200119.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|